Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CD69 | Q07108 | 1/20 | 0.50 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.50 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.50 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13780934 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL15334479 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL13781334 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL14819154 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL23602189 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL20904146 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL24299983 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL14268514 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL5172619 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL16392567 | 1.00 | MAPK1 (0.62) | MAPK1ALDH1A1THRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6387961-B1 | OIL IN WATER EMULSIONS EMULSIFIERS | BEIERSDORF AG (DE) | 2002-05-14 | — | — | US | claimed |
| US-6156326-A | Alkyl 2-acetamido-2-deoxyglucopyranoside uronic acids and derivatives, their preparation and their use as surfactants in cosmetic and pharmaceutical preparations | BEIERSDORF AG (DE) | 2000-12-05 | — | — | US | claimed |
| US-6037460-A | FOR SURFACTANTS, DETERGENTS OR EMULSIFERS ESPECIALLY COSMETIC CLEANSING AGENTS | BEIERSDORF AG (DE) | 2000-03-14 | — | — | US | claimed |
| US-20240216491-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2024-07-04 | — | — | US | disclosed |
| US-11925680-B2 | Neoglycoconjugates as vaccines and therapeutic tools | KORANEX CAPITAL (CA) | 2024-03-12 | — | — | US | disclosed |
| EP-4034159-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | Koranex Capital (CA) | 2022-08-03 | — | — | EP | disclosed |
| US-10973910-B1 | Neoglycoconjugates as vaccines and therapeutic tools | KORANEX CAPITAL (CA) | 2021-04-13 | — | — | US | disclosed |
| WO-2021056098-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2021-04-01 | — | — | WO | disclosed |
| US-20210085781-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2021-03-25 | — | — | US | disclosed |
| US-20210085770-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2021-03-25 | — | — | US | disclosed |
| US-20200261560-A1 | PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2020-08-20 | — | — | US | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| EP-0576592-A4 | OLIGOSACCHARIDE ENZYME SUBSTRATES AND INHIBITORS: METHODS AND COMPOSITIONS | SCRIPPS RESEARCH INST (US) | 1996-01-24 | — | — | EP | disclosed |
| US-5461143-A | Oligosaccharide enzyme substrates and inhibitors: methods and compositions | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-10-24 | — | — | US | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| US-5374541-A | Combined use of β-galactosidase and sialyltransferase coupled with in situ regeneration of CMP-sialic acid for one pot synthesis of oligosaccharides | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-12-20 | — | — | US | disclosed |
| EP-0576592-A1 | OLIGOSACCHARIDE ENZYME SUBSTRATES AND INHIBITORS: METHODS AND COMPOSITIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0570682-A1 | Synthetic lipid A glycoconjugate antigens for use in vaccines | AMERICAN CYANAMID COMPANY (US) | 1993-11-24 | — | — | EP | disclosed |
| WO-1992016640-A1 | OLIGOSACCHARIDE ENZYME SUBSTRATES AND INHIBITORS: METHODS AND COMPOSITIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210085770-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | GNE, B3GNT2, KRTCAP2 | MAPK1 3897/4885ALDH1A1 4018/4885THRB 2966/4885 |
| US-20240216491-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | GNE, B3GNT2, KRTCAP2 | MAPK1 3897/4885ALDH1A1 4018/4885THRB 2966/4885 |
| US-20210085781-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | GNE, B3GNT2, KRTCAP2 | MAPK1 3897/4885ALDH1A1 4018/4885THRB 2966/4885 |
| US-20200261560-A1 | PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS | STT3B, STT3A, SIGLEC7 | MAPK1 3839/4885ALDH1A1 1454/4885THRB 2935/4885 |
| US-11925680-B2 | Neoglycoconjugates as vaccines and therapeutic tools | GNE, B3GNT2, KRTCAP2 | MAPK1 3897/4885ALDH1A1 4018/4885THRB 2966/4885 |
| US-10973910-B1 | Neoglycoconjugates as vaccines and therapeutic tools | GNE, B3GNT2, KRTCAP2 | MAPK1 3897/4885ALDH1A1 4018/4885THRB 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.